Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 4/20 | 0.33 |
| ▸ | HTR7 | P34969 | 4/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24939944 | 0.94 | PTPN1 (0.35) | GSK3AGSK3BNPY1RCYP2D6CHRM1 | |
| SCHEMBL24938953 | 0.93 | NPY1R (0.41) | NPY1RCYP2D6CHRM1HTR2AHRH1 | |
| SCHEMBL24939893 | 0.93 | SMN1; SMN2 (0.36) | NPY1RCYP2D6CHRM1HTR2AHRH1 | |
| SCHEMBL24939986 | 0.93 | CYP2D6 (0.42) | NPY1RCYP2D6CHRM1HTR2AHRH1 | |
| SCHEMBL24939992 | 0.93 | NPY1R (0.33) | NPY1RCYP2D6CHRM1HTR2AHRH1 | |
| SCHEMBL23303909 | 0.88 | NPY1R (0.35) | NPY1RALDH1A1PARP1 | |
| SCHEMBL29695401 | 0.88 | NPY1R (0.35) | NPY1RALDH1A1PARP1 | |
| SCHEMBL23302562 | 0.88 | NPY1R (0.35) | NPY1RALDH1A1PARP1 | |
| SCHEMBL24938894 | 0.85 | NPY1R (0.35) | NPY1RCYP2D6CHRM1HTR2AHRH1 | |
| SCHEMBL24939989 | 0.84 | NPY1R (0.36) | NPY1RHTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019094-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME | HOLOSMEDIC (KR) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019094-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCC1 | GSK3A 1714/4885GSK3B 1476/4885NPY1R 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.